Annexon (ANNX) Depreciation & Amortization (CF) (2019 - 2026)
Annexon (ANNX) posted quarterly Depreciation & Amortization (CF) of $539000.0 for Q1 2026, little changed year-over-year from $537000.0 in Q1 2025, and down 0.74% quarter-over-quarter from $543000.0 in Q4 2025.
Analysis
Annexon (ANNX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Annexon's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $539000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.37% year-over-year to $539000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 0.88% YoY), while the FY2025 annual figure was $2.2 million, up 0.74% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $539000.0, down from $543000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $546000.0 in Q3 2025, with the low at $518000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $538000.0 (2023), against an average of $535823.5.
- Peak annual rise in Depreciation & Amortization (CF) reached 4.74% in 2022, while the deepest fall reached 7.33% in 2022.
- Annexon's Depreciation & Amortization (CF) stood at $530000.0 in 2022, then increased by 1.51% to $538000.0 in 2023, then declined by 0.19% to $537000.0 in 2024, then advanced by 1.12% to $543000.0 in 2025, then slipped by 0.74% to $539000.0 in 2026.
- Business Quant data shows ANNX's Depreciation & Amortization (CF) at $539000.0 in Q1 2026, $543000.0 in Q4 2025, and $546000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Annexon | 970.85 Mn | 970.85 Mn | - | 540,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 540,000.00 |
| Mar 31, 2026 | 539,000.00 |
| Dec 31, 2025 | 543,000.00 |
| Sep 30, 2025 | 546,000.00 |
| Jun 30, 2025 | 540,000.00 |
| Mar 31, 2025 | 537,000.00 |
| Dec 31, 2024 | 537,000.00 |
| Sep 30, 2024 | 538,000.00 |
| Jun 30, 2024 | 537,000.00 |
| Mar 31, 2024 | 538,000.00 |
| Dec 31, 2023 | 538,000.00 |
| Sep 30, 2023 | 538,000.00 |
| Jun 30, 2023 | 536,000.00 |
| Mar 31, 2023 | 536,000.00 |
| Dec 31, 2022 | 530,000.00 |
| Sep 30, 2022 | 518,000.00 |
| Jun 30, 2022 | 540,000.00 |
| Mar 31, 2022 | 518,000.00 |
| Dec 31, 2021 | 506,000.00 |
| Sep 30, 2021 | 559,000.00 |